Organon & Co.

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

OGN$13.85-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

($ in millions except shares in thousands and per share amounts)

	December 31, 2023	December 31, 2022
Assets
Current Assets:
Cash and cash equivalents	$693	$706
Accounts receivable (net of allowance for doubtful accounts of $9 in 2023 and $9 in 2022)	1,744	1,475
Inventories (excludes inventories of $110 in 2023 and $148 in 2022 classified in Other assets)	1,315	1,003
Other current assets	756	747
Total Current Assets	4,508	3,931
Property, plant and equipment, net	1,183	1,018
Goodwill	4,603	4,603
Intangibles, net	533	649
Other assets	1,231	754
Total Assets	$12,058	$10,955
Liabilities and Equity
Current Liabilities:
Current portion of long-term debt	$9	$8
Trade accounts payable	1,314	1,132
Accrued and other current liabilities	1,389	1,188
Income taxes payable	206	184
Total Current Liabilities	2,918	2,512
Long-term debt	8,751	8,905
Deferred income taxes	47	19
Other noncurrent liabilities	412	411
Total Liabilities	12,128	11,847
Contingencies (Note 20)
Organon & Co. Stockholders' Deficit:
Common stock, $0.01 par valueAuthorized - 500,000Issued and outstanding - 255,626 in 2023 and 254,370 in 2022	3	3
Additional paid-in capital	25	—
Retained earnings and accumulated (deficit)	443	(331)
Accumulated other comprehensive loss	(541)	(564)
Total Stockholders' Deficit	(70)	(892)
Total Liabilities and Stockholders' Deficit	$12,058	$10,955

-56-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.